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METABOLICALLY UNHEALTHY 
OBESITY (MUO)
BMI: body mass index; BP: blood pressure; CVD: cardiovascular disease; HDL-C: high-density lipoprotein cholesterol; 
MPO: myeloperoxidase; PAI-1: plasminogen activator inhibitor 1; TG: triglycerides.
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Abstract 
Background and aims. The early onset of cardio-metabolic abnormalities, known as 
metabolically unhealthy (MU) status, is highly associated with obesity and cardiovascular 
disease (CVD), as well as with increased morbidity and mortality later in life. Given the lack of a 
consensus MU classification for prepubertal children, we aimed to compare available MU 
definitions in terms of their association with CVD risk biomarkers. 
Methods and results. A total of 930 prepubertal children (622 with overweight/obesity, 462 
males) aged 5 to 10.9 years were recruited, anthropometric measures were taken and 
biomarkers were analyzed. Children were classified using eight MU definitions based on 
different cut-offs for blood pressure, triacylglycerides, high-density lipoprotein cholesterol, 
glucose and homeostasis model assessment for insulin resistance (HOMA-IR). MU prevalence 
in children with overweight/obesity ranged between 30% and 60% across definitions. Plasma 
concentrations of resistin, leptin, myeloperoxidase (MPO) and total plasminogen activator 
inhibitor 1 (tPAI-1) were higher, and those of adiponectin were lower, in MU compared to MH 
children with overweight/obesity. Linear regression analyses confirmed the contribution of 
MPO and tPAI-1 concentrations to MU status, with most significant results derived from 
definitions that use age and sex-specific criteria and that account for HOMA-IR. 
Conclusion. Plasma concentrations of MPO and tPAI-1 are increased in prepubertal MU 
children irrespective of having normal-weight or overweight/obesity. Inclusion of age and sex-
specific cut-offs for cardio-metabolic components as well as insulin resistance criteria increases 
the quality of MU definitions as seen by their stronger association with CVD biomarkers 
concentrations.  
 
Keywords: cardiovascular disease, metabolic health, insulin resistance, childhood obesity. 
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Introduction 
Childhood obesity is one of the most serious public health issues of the 21st century. Results 
from the most recent study in Spain indicated that 33% of children aged 6 to 9 years had 
overweight or obesity according to the International Obesity Task Force (IOFT) criteria [1]. 
Obesity in children is associated with an altered adipokine profile and a high risk of metabolic 
complications that may appear at very early ages [2, 3]. Moreover, the onset of obesity in early 
infancy is also associated with an increased risk of future cardio-metabolic disorders and 
premature mortality [4]. 
However, it has been shown that not all individuals with obesity exhibit metabolic 
disturbances. Obesity that is not associated with cardio-metabolic abnormalities is termed 
metabolically healthy (MH) obesity (MHO), whereas obesity with metabolic alterations is called 
metabolically unhealthy (MU) obesity (MUO). Notably, normal-weight individuals can also 
exhibit a MU profile, which also increases disease risk for this population, independently of 
obesity [5]. 
Children are commonly classified as MU when there is a state of insulin resistance (IR) or when 
one or more cardio-metabolic criteria, namely, hypertension, dyslipidemia, or altered glucose 
metabolism, which are features of the so-called metabolic syndrome, are present. However, 
there is no consensus definition to identify and classify MU children, which complicates the 
interpretation of available results [6]. 
To this date, increased concentrations of circulating CVD risk biomarkers have been observed in 
children [2, 3, 7] as well as in MU adults [8] with obesity. However, there is a need of studies 
assessing CVD risk in MU prepubertal children. 
Therefore, the present study aimed to: 1) examine the prevalence of MU status in prepubertal 
Spanish children with and without overweight/obesity according to eight MU definitions, 2) 
analyze the differences in CVD risk biomarkers among children with MU status, with and 
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without overweight/obesity, and 3) assess the usefulness of available MU definitions based on 
their association with the identified CVD risk biomarkers. 
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Methods 
Study Population 
A total of 930 prepubertal children (308 normal-weight and 622 overweight/obesity, 462 males 
and 468 females) aged 5 to 10.9 years were recruited from primary care centers and schools in 
three Spanish cities (Cordoba, Santiago de Compostela, and Zaragoza). Inclusion criteria were: 
prepubertal stage (Tanner I) and absence of metabolic diseases. Exclusion criteria were: Tanner 
stage II to V and use of medications for blood pressure (BP), glucose, or lipid metabolism. 
Children were assessed as described in previous studies [3]. Parents or guardians were 
informed of the purpose and procedures of the study before written consents were obtained. 
The Ethics Committees of all participating institutions approved the study, which complied with 
the Declaration of Helsinki (Edinburgh 2000 revised). 
Anthropometric Measures 
Anthropometric parameters and systolic and diastolic BP (SBP and DBP, respectively) were 
measured and BMI was calculated (kg/m
2
). Overweight and obesity were defined using age- 
and sex-specific BMI cut-off points, equivalent to adult values of 25 kg/m
2
 for overweight and 
30 kg/m
2
 for obesity [9]. The Z-Score for BMI (BMI-z) was calculated as previously [2]. 
Biomarker Analysis 
Blood samples were drawn after an overnight fast and routine analyses were performed at 
each participating hospital as previously [2]. Plasma insulin was analyzed using 
radioimmunoassay (CV: 2.6%) in an automatic microparticle analyzer (AxSYM; Abbott 
Laboratories, Chicago, Ill., USA) and homeostasis model assessment for insulin resistance 
(HOMA-IR) was calculated. Plasma aliquots were centrifuged and stored at -80°C for later 
analyses of active and total plasminogen activator inhibitor 1 (PAI-1), soluble intercellular 
adhesion molecule 1 (sICAM-1), soluble endothelial selectin (sE-selectin), soluble vascular 
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adhesion molecule 1 (sVCAM-1), matrix metalloproteinase 9 (MMP-9), high sensitivity C-
reactive protein (hsCRP), tumor necrosis factor alpha (TNF-α), interleukins (IL) 6 and IL-8, and 
myeloperoxidase (MPO) [2, 10]. SE-selectin was measured in a subsample of the population 
due to changes in the commercial kit used for analyses. From these, candidate biomarkers of 
MU status were selected. 
MH/MU Classification 
Children were classified according to: A) five definitions based on metabolic syndrome 
components: Olza et al.[11], Ahrens et al. [12], Li et al. [13], IDF [14] and Reinehr et al. [15], 
and B) three definitions based on HOMA-IR cut-offs: Olza et al. [11], Prince et al. [16], and Li et 
al. [13] (Table 1). The fulfillment of at least one criterion was indicative of MU status. We 
accessed all references and their corresponding charts or tables to classify the children, using 
the same cut-off points or percentiles as in the original studies. 
Statistical Analysis 
Results are expressed as the means ± SEM. Variables with a non-normal distribution were 
transformed. HOMA-IR, tPAI-1, MMP-9, and TNF-α were logarithmically transformed, and 
insulin, HDL-cholesterol (HDL-C) and sE-Selectin were square-root transformed. Biomarker 
circulating concentrations were compared among four groups: 1) MH normal-weight, 2) MU 
normal-weight, 3) MH overweight/obesity and 4) MU overweight/obesity, using a general 
linear model adjusted for age. Differences between pairs of means were assessed using a 
pairwise Bonferroni post-hoc test. An additional adjustment for BMI was conducted to discard 
findings exclusively due to increased adiposity.  
The kappa (κ) coefficient evaluated agreement between MU definitions, considering a κ value 
of less than 0.2 as poor, 0.2 through 0.4 as marginal, 0.4 through 0.6 as moderate, 0.6 through 
0.8 as strong, and above 0.8 as very strong [17].  
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For both tPAI-1 and MPO (dependent variables), their association with MU status (independent 
variable) was evaluated by backward-step linear regression for each definition, including age 
and gender in the analysis, stratifying by BMI status (normal-weight and overweight/obesity). 
P<0.05 was considered significant. Sample size calculations were conducted using a power of 
80% (beta error = 0.20) and a confidence interval of 95% (alpha I error of 0.05), considering 
previously reported MPO concentrations in children, showing a 20-25% difference between 
children with obesity and normal-weight [2, 3]. A minimum sample size of 167 per group was 
obtained. All statistical analyses were performed using the Statistical Package for Social Science 
software (IBM SPSS 24, IBM Corporation, Somers, N.Y., USA). 
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Results 
Table 2 shows the main characteristics of the children participating in the study according to 
gender. Some significant differences were observed for anthropometry, glucose, and lipid 
metabolism parameters. 
Percentages of MUO children according to the studied definitions ranged between 14% and 
70% and are shown in Figure 1. Data from the total population is shown because similar results 
were observed in males and females (Table S1). The highest proportions of MUO children were 
observed when the definitions of Olza et al.[11], Ahrens et al. [12] and Li et al. [13] were used, 
and the lowest proportions were observed with the definitions of IDF [14], Reinehr et al. [15] 
and with IR-based definitions. MU prevalence among normal-weight children ranged between 
1.7% and 25% across definitions (Table S2). The highest Cohen’s Kappa agreement was 
observed between Olza et al. [11], Ahrens et al. [12] and Li et al. [13] definitions (Table S3). 
Regarding IR-based definitions, the highest agreement was observed between Olza et al. [11]-
IR and Li et al. [13]-IR definitions (Table S4). 
Biomarker differences among the studied groups are shown in Table 3, with children classified 
according to Olza et al. MU definition [11]. Since findings were similar for both males and 
females, results are shown for the total population. Plasma concentrations of resistin were 
significantly higher in MU individuals compared to their MH counterparts, independently of 
BMI status. Leptin concentrations were also higher in MU individuals, although children with 
overweight/obesity displayed higher values than children with normal-weight. Plasma 
adiponectin showed lower concentrations in the MU overweight/obesity group compared to 
MH children. Concerning CVD risk biomarkers, MU children with overweight/obesity exhibited 
higher concentrations of tPAI-1 and MPO than MH individuals, even after an additional 
adjustment for BMI. Given their clear differences between MH and MU children, MPO and 
tPAI-1 were selected for successive analyses. 
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In children with overweight/obesity, linear regression analysis showed significant associations 
between MU status and the selected CVD biomarkers tPAI-1 and MPO, according to the 
definitions of Olza et al. [11], Ahrens et al. [12], Li et al. [13], Olza et al. [11]-IR and Li et al. [13]-
IR. The observed associations in children with normal-weight were similar, although less 
significant.  
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Discussion 
Available definitions of MUO for children share multiple criteria, but there is no consensus 
definition for the classification of children at risk of cardio-metabolic disturbances. To our 
knowledge, this is the first study to demonstrate an association between MU status and CVD 
risk biomarkers (tPAI-1 and MPO) in prepubertal children using different definitions. 
Our first analysis showed that the classification of children as MH or MU varied across 
definitions, finding the double of MUO prevalence with the definitions of Olza et al. [11] or 
Ahrens et al. [12] than with those of IDF [14] or Reinehr et al. [15] (~65% vs. ~30%) (Figure 1). 
Previous studies revealed ~30 to 75% of MUO children and adolescents with obesity. However, 
none of these studies were performed exclusively in prepubertal children [6, 13]. Importantly, 
we also found up to a 25% prevalence of MU among children with normal-weight. The most 
likely reason for the variability of prevalence is the higher specificity of the criteria used within 
the metabolic syndrome-based classifications of Olza et al. [11] and Ahrens et al. [12], which 
account for age and gender in the assessment of TAG, HDL-C and BP. Moreover, these 
definitions also include a HOMA-IR cut-off, which could improve their quality of the 
classification given the association that exists between insulin resistance and other metabolic 
disturbances in MU individuals (Table 1). In contrast, the more general criteria in other 
classifications may lead to false negative results, lowering the prevalence. Finally, definitions 
solely based in HOMA-IR cut-offs revealed lower prevalence, with the definition of Prince et al. 
[16] showing the lowest prevalence given its higher HOMA-IR cut-off (Table 1). This finding is 
not surprising since HOMA-IR classifications miss MU children that fulfill other criteria. 
The observed adipokine status agrees with previous findings in which MUO individuals display 
altered adipokine circulating levels derived from excessive adipose tissue [18]. We observed 
higher leptin and resistin and lower adiponectin concentrations in the MU overweight/obesity 
group compared to the MH groups. Similarly, leptin has been associated with MUO in children 
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and adolescents [19] and resistin has been observed to be increased in adolescents with 
obesity and metabolic syndrome [20] and in the presence of abdominal obesity [3] and fat 
mass [21] in children. However, to the best of our knowledge, our study is the first to describe 
the association between resistin and MH/MU status in prepubertal children. Concerning 
adiponectin, our findings confirm previous studies in which its levels were negatively 
associated with body fat, obesity-related metabolic abnormalities and MUO risk in children and 
adolescents [2, 3, 18, 19, 22]. Therefore, we show that the derangement of adipokine profile 
begins at prepubertal stage in MU children, principally through the alteration of resistin and 
adiponectin, and that this occurs beyond BMI status. 
Regarding CVD risk biomarkers, they differed across MH and MU normal-weight and 
overweight/obesity groups of prepubertal children, highlighting tPAI-1 and MPO, which were 
increased in MU individuals. Moreover, the regression analysis confirmed the association 
between MU status and these biomarkers in children with overweight/obesity but also, to 
some extent, in those with normal-weight. PAI-1 was selected for successive analyses given its 
association with increased thrombosis and atherosclerosis risk [23, 24]. In addition, PAI-1 
plasma concentrations have been observed to be increased in MUO adults [5, 8] and children 
with obesity [3] and metabolic syndrome [7]. The present study shows it is already increased in 
MU children independently of their BMI status. A possible explanation for the BMI-
independent association between PAI-1 and MU status could be that circulating PAI-1 may be 
synthesized in the liver in addition to adipose tissue [23]. [As for MPO, a pro-oxidant enzyme 
released by leukocytes, it was also selected for the comparison of definitions given its previous 
association with endothelial function in children with obesity [25] as well as with other CVD 
risk and pro-inflammatory biomarkers [2, 26]. Altogether, the increase in PAI-1 and MPO 
concentrations in MU children with overweight/obesity as early as in the prepubertal stage 
indicates the importance of these molecules in the increased cardio-metabolic risk in children.  
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Other CVD risk biomarkers such as sE-Selectin, sICAM-1, sVCAM-1 and MMP-9 were increased 
in children with overweight/obesity but did not differ according to MU status, as previously 
observed in children [27], adolescents [28] and young adults [29]. The same was observed for 
pro-inflammatory biomarkers, as the increase of hsCRP, IL-6, and TNF-α concentrations was 
due to obesity, as previously shown [5, 8]. 
As for the adequacy of MU definitions to detect children presenting CVD risk biomarker 
derangement, prevalence and linear regression results highlight the importance of the applied 
cardio-metabolic criteria. The fact that classifications of Olza et al. [11] and Ahrens et al. [12] 
account for age and gender in the assessment of TAG, HDL-C and BP, arises as an essential 
aspect (Table 1). Moreover, the significant linear regression results derived from MU definitions 
exclusively based on HOMA-IR cut-offs, despite their lowest reported MU prevalence, support 
the importance of the inclusion of this criterion, as it increases the quality and power of the 
definition to find children with overweight/obesity with a MU status. 
Although fat accumulation remains an independent risk factor for MU, our study demonstrated 
that MU status is also associated with an altered CVD risk biomarker profile in prepubertal 
children with either normal-weight or overweight/obesity. The limited associations observed in 
our study may be due to a situation in which the cardio-metabolic derangement is in progress, 
as well as to the prepubertal character of the population. Stronger associations with MUO will 
most likely become apparent at later stages in life, as indicated by previous studies in 
adolescents, young adults and older adults [8, 19, 29].  
The present study has strengths and limitations. Strengths include the sample size, the 
prepubertal character of the population, avoiding puberty associated physiological, hormonal 
and metabolic alterations that may confound the observed results [15], the inclusion of 
normal-weight children and the exhaustive analysis of a wide variety of adipokines and CVD 
biomarkers. Limitations include the absence of a clinical correspondent of CVD, the 
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development of Olza et al. [11] definition within a population shared with the present study 
and the determination of sE-Selectin in a subsample of the population. 
We found that adiponectin was decreased and leptin, resistin, tPAI-1, and MPO were increased 
in MU prepubertal children independently of their weight status. Moreover, we observed that 
MU definitions using sex- and age-specific criteria and accounting for HOMA-IR reveal the 
highest MU prevalence in children with overweight/obesity, as well as the strongest 
associations with CVD risk biomarkers. Therefore, these definitions should be used in further 
studies and clinical practice. 
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Figure Legends 
Figure 1 Prevalence of metabolically healthy and unhealthy prepubertal children with 
overweight/obesity according to different classification criteria. MHO: metabolically healthy 
overweight/obesity; MUO: metabolically unhealthy overweight/obesity. 
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Tables 
Table 1 Definitions of metabolically unhealthy (MU) status in children compared in the present study. 
Definition Age range 
Population 
weight status 
Blood Pressure TAG HDL-C Glucose HOMA-IR 
Olza et al. (11) 5-18 y NW 
OW 
OB 
SBP or DBP ≥90th 
percentile for age, 
sex, and height 
>90th percentile 
for age, sex, and 
race 
<10th percentile 
for age, sex, and 
race 
≥100 mg/dL > 2.5 
Ahrens et al. (12) 2-11 y NW 
OW 
OB 
SBP or DBP ≥90th 
percentile for age, 
sex, and height 
≥90th percentile 
for age and sex  
≤ 10th percentile 
for age and sex  
≥ 90th 
percentile for 
age and sex  
≥ 90th 
percentile for 
age and sex  
Li et al. (13) 6-11 y OB SBP or DBP ≥90th 
percentile for age, 
sex, and height 
≥110 mg/dL < 40 mg/dL ≥100 mg/dL  
IDF (14) 6-<16 y  SBP≥130 or DBP≥85 ≥150 mg/dL < 40 mg/dL ≥100 mg/dL  
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Reinehr et al. (15) 11.6 ± 2.8 y OB BP > 95th percentile 
for age and sex 
> 150 mg/dL < 40 mg/dL ≥100 mg/dL  
Olza et al. (11)-IR 5-18 y NW 
OW 
OB 
    > 2.5 
Prince et al. (16)-
IR 
8-17 y OW 
OB 
    ≥ 3.16 
Li et al. (13)-IR 6-18 y OB     > 2.3 
 
MU status was considered when at least one criterion was fulfilled. BP: blood pressure; DBP: diastolic blood pressure; HDL-C: HDL cholesterol; 
HOMA-IR: homeostasis model assessment for insulin resistance; NW: normal-weight; OB: obesity; OW: overweight; SBP: systolic blood pressure; 
TAG: triacylglycerides. 
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Table 2 General characteristics of the population included in the study  
  Male (N= 462) Female (N=468) 
Anthropometry 
Age (y) 8.7 (1.4) 8.4 (1.5)* 
Weight (kg) 40.3 (13.8) 38.8 (11.7) 
Height (m) 1.3 (0.1) 1.3 (0.1)* 
Overweight/obesity (%) 69.9 64.1 
BMI (kg/m
2
) 21.9 (5.5) 21.8 (4.9) 
BMI-z  1.99 (2.24) 1.53 (1.60)* 
Hip Circ (cm) 79.4 (11.8) 79.1 (9.9) 
Waist/Hip C 0.91 (0.08) 0.90 (0.07) 
WC (cm) 71.9 (15.9) 70.9 (13.7) 
WC/Height 0.54 (0.10) 0.53 (0.09) 
SBP (mm Hg) 102.8 (14.7) 103.9 (12.4) 
DBP (mm Hg) 63.2 (11.6) 64.3 (10.8) 
Glucose metabolism 
Glucose (mg/dl) 85 (7) 83 (7)* 
Insulin (mU/l)
 +
 7.6 (6.0) 8.6 (5.9)* 
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  Male (N= 462) Female (N=468) 
HOMA-IR
+
 1.60 (1.37) 1.78 (1.28)* 
Lipid metabolism 
CHOL (mg/dl) 170 (32) 169 (29) 
TAG (mg/dl) 62 (32) 69 (36)* 
HDL-C (mg/dl)
 +
 59 (15) 55 (14)* 
LDL-C (mg/dl) 97 (28) 98 (26) 
HDL/LDL 0.69 (0.39) 0.64 (0.42) 
APO A (mg/dl) 145 (31) 140 (29)* 
APO B (mg/dl) 67 (19) 70 (18)* 
APO B/LDL 0.72 (0.15) 0.73 (0.16) 
APO A/APO B 2.30 (0.76) 2.11 (0.72)* 
Data are mean (SD). * Significant differences (P<0.05) between genders. 
+
 P-values for transformed 
variables are based on transformed differences. 
APO: apolipoprotein; BMI: body mass index; CHOL: cholesterol; DBP: diastolic blood pressure; HDL-C: HDL 
cholesterol; Hip Circ: Hip circumference; HOMA-IR: homeostatic model assessment-insulin resistance; LDL-
C: LDL cholesterol; QUICKI: quantitative insulin sensitivity check index; SBP: systolic blood pressure; TAG: 
triacylglycerides; WC: waist circumference.
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Table 3 Adipokines and CVD risk biomarkers of the studied population classified according to the metabolically unhealthy definition of Olza et al. 
(11) 
  Normal-weight Overweight/Obesity  
  MH MU MH MU P (ANCOVA) 
  N Mean  SEM N Mean  SEM N Mean  SEM N Mean  SEM Age Age+BMI 
Adipokines 
Adiponectin (mg/l) 191 24.76 ± 0.86a 57 20.93 ± 1.42ab 194 21.92 ± 0.91a 310 18.75 ± 0.55b 0.000 0.008 
Resistin (µg/l) 191 12.25 ± 0.78a 57 15.87 ± 1.82ab 194 12.43 ± 0.68a 309 15.32 ± 0.58b 0.001 0.010 
Leptin (µg/l) 189 3.61 ± 0.28a 54 4.65 ± 0.60a 193 12.73 ± 0.66b 314 19.79 ± 0.79c 0.000 0.022 
L:A ratio 188 0.18 ± 0.02 54 0.29 ± 0.05 193 2.25 ± 1.16 310 1.39 ± 0.08 0.095 0.381 
CVD risk biomarkers 
Total PAI-1 (µg/l)* 192 16.89 ± 0.81a 57 21.41 ± 2.07ab 192 22.77 ± 1.07b 311 26.99 ± 0.98c 0.000 0.011 
Active PAI-1 (µg/l) 152 5.10 ± 0.32a 44 5.35 ± 0.82a 146 9.27 ± 0.65b 201 12.66 ± 0.76c 0.000 0.394 
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 6 
  Normal-weight Overweight/Obesity  
  MH MU MH MU P (ANCOVA) 
  N Mean  SEM N Mean  SEM N Mean  SEM N Mean  SEM Age Age+BMI 
sE-Selectin (µg/l)* 40 72.02 ± 14.25a 13 151.07 ± 49.82ab 47 61.90 ± 14.85ab 110 60.33 ± 7.05b 0.000 0.389 
sICAM-1 (mg/l) 192 0.15 ± 0.01 57 0.15 ± 0.01 191 0.16 ± 0.01 311 0.17 ± 0.01 0.185 0.931 
sVCAM-1 (mg/l) 150 1.19 ± 0.03a 44 1.25 ± 0.04ab 146 1.10 ± 0.03bc 199 1.06 ± 0.02c 0.000 0.832 
MMP-9 (µg/l)* 152 85.91 ± 3.75 44 95.65 ± 9.00 145 88.07 ± 4.72 201 88.70 ± 4.38 0.689 0.676 
MPO (µg/l) 191 19.70 ± 2.53a 57 34.66 ± 6.05ab 194 19.85 ± 1.77a 309 32.63 ± 2.64b 0.000 0.001 
hsCRP (mg/l) 205 1.44 ± 0.54a 65 2.21 ± 1.12ab 197 3.40 ± 0.44b 322 3.29 ± 0.21b 0.002 0.410 
IL-6 (ng/l) 179 4.13 ± 0.56 56 2.69 ± 0.63 185 4.52 ± 0.79 312 5.34 ± 0.62 0.230 0.737 
IL-8 (ng/l) 188 1.69 ± 0.12a 58 1.65 ± 0.17ab 190 2.10 ± 0.20ab 310 2.42 ± 0.16b 0.006 0.791 
TNF-α (ng/l)* 192 3.06 ± 0.12ab 58 2.92 ± 0.25a 191 3.62 ± 0.15bc 314 3.76 ± 0.13c 0.000 0.614 
ANCOVA adjusted by age or age and BMI as indicated. Mean values within the same row not sharing the same superscript letter were 
significantly different by the Bonferroni post-hoc test. * P-values for transformed variables are based on transformed differences. 
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 7 
hsCRP: high sensitivity C reactive protein; IL-6: interleukin 6; IL-8: interleukin 8; L:A ratio: leptin:adiponectin ratio; MH: metabolically healthy; 
MMP-9: matrix metalloproteinase 9; MPO: myeloperoxidase; MU: metabolically unhealthy; N: number of samples; PAI-1: plasminogen activator 
inhibitor 1; SEM: standard error of the mean; sICAM-1: soluble intercellular adhesion molecule 1; sE-selectin: soluble endothelial selectin; 
sVCAM-1: soluble vascular adhesion molecule 1; TNF-α: tumor necrosis factor alpha.
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Table 4 Association between metabolically unhealthy definitions and plasma concentrations of 
cardiovascular disease risk biomarkers in prepubertal children. 
Classification 
tPAI-1 MPO 
Βeta 
NW 
P NW Βeta 
OW/OB 
P 
OW/OB 
Βeta 
NW 
P NW Βeta 
OW/OB 
P 
OW/OB 
Olza et al. (11) 0.118 0.068 0.137 0.002 0.174 0.007 0.158 0.000 
Ahrens et al. (12) 0.143 0.026 0.176 0.000 0.133 0.039 0.120 0.007 
Li et al. (13) 0.106 0.099 0.094 0.035 0.112 0.082 0.079 0.076 
IDF (14) 0.105 0.098 0.032 0.469 -0.005 0.934 -0.027 0.542 
Reinehr et al. (15) 0.108 0.093 0.079 0.077 0.078 0.227 0.085 0.057 
Olza et al. (11)-IR 0.130 0.038 0.147 0.001 0.064 0.305 0.116 0.010 
Prince et al. (16)-IR 0.148 0.018 0.120 0.008 0.086 0.173 0.042 0.348 
Li et al. (13)-IR 0.120 0.055 0.173 0.000 0.110 0.079 0.109 0.015 
Beta: standardized beta coefficient; IR: insulin resistance; NW: normal-weight; OW/OB: 
overweight/obesity; P: significance of the linear regression adjusted for age and sex; MPO: 
myeloperoxidase; tPAI-1: total plasminogen activator inhibitor 1. 
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Highlights 
• Prevalence of metabolically unhealthy (MU) children varies with definitions. 
• Age and sex-specific MU definitions including HOMA-IR show higher MU prevalence. 
• MU status is associated with higher concentrations of tPAI-1 and MPO. 
• MU definitions considering HOMA-IR show stronger associations with MPO and tPAI-1. 
 
